Journal
INTERNATIONAL JOURNAL OF PHARMACEUTICS
Volume 599, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.ijpharm.2021.120443
Keywords
Inkjet; 3D printing; Biopharmaceutical printing; Digital manufacturing
Categories
Funding
- UK Engineering and Physical Sciences Research Council Doctoral Training Partnerships
- EPSRC [EP/S009000/1]
- BBSRC [BB/T011750/1]
- BBSRC [BB/T011750/1] Funding Source: UKRI
Ask authors/readers for more resources
The pharmaceutical industry is shifting towards biologics from small molecule drugs globally, driven by the need for more targeted treatments. Researchers and companies are facing shared challenges in developing biopharmaceuticals, including considering mechanical and chemical influences during manufacturing and selecting appropriate hardware.
There is an ongoing global shift in pharmaceutical business models from small molecule drugs to biologics. This increase in complexity is in response to advancements in our diagnoses and understanding of diseases. With the more targeted approach coupled with its inherently more costly development and manufacturing, 2D and 3D printing are being explored as suitable techniques to deliver more personalised and affordable routes to drug discovery and manufacturing. In this review, we explore first the business context underlying this shift to biopharmaceuticals and provide an update on the latest work exploring discovery and pharmaceutics. We then draw on multiple disciplines to help reveal the shared challenges facing researchers and firms aiming to develop biopharmaceuticals, specifically when using the most commonly explored manufacturing routes of drop-on-demand inkjet printing and pneumatic extrusion. This includes separating out how to consider mechanical and chemical influences during manufacturing, the role of the chosen hardware and the challenges of aqueous formulation based on similar challenges being faced by the printing industry. Together, this provides a review of existing work and guidance for researchers and industry to help with the de-risking and rapid development of future biopharmaceutical products.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available